Ken Griffin Day One Biopharmaceuticals, Inc. Transaction History
Citadel Advisors LLC
- $550 Billion
- Q2 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 703,644 shares of DAWN stock, worth $5.26 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
703,644
Previous 11,800
5863.08%
Holding current value
$5.26 Million
Previous $93,000
4817.2%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding DAWN
# of Institutions
188Shares Held
69.3MCall Options Held
127KPut Options Held
85.5K-
Atlas Venture Life Science Advisors, LLC6.43MShares$48 Million9.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.18MShares$46.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$33.9 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA4.1MShares$30.6 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.72MShares$27.8 Million0.56% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $549M
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...